Oxaliplatin-d10

Oxaliplatin-d10 is a deuterium labeled Oxaliplatin. Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].

1132819-16-9

12352005

H302

Apoptosis; DNA/RNA Synthesis; Isotope-Labeled Compounds

Isotope-Labeled Compounds

Apoptosis; Cell Cycle/DNA Damage; Others

Cancer-programmed cell death

Cancer

10 mM in DMSO

O=C1[O-][Pt+2]2([O-]C1=O)[NH2][C@@]3([2H])[C@](C([2H])([2H])C([2H])([2H])C([2H])([2H])C3([2H])[2H])([2H])[NH2]2

C8H4D10N2O4Pt

407.35

H302

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-246.|[2]Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52 (5) :341-347.|[3]Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794 (10) :1433-40.|[4]Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109 (30) :11987-92.|[5]Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11 (10) :859-63.|[6]Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9 (10) :1053-71.|[7]Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18 (11) :1595-604|[8]Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53 (24) :5970-6.|[9]Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43 (4) :237-50.|[10]Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7 (9) :e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.

Room Temperature

4°C (Powder, stored under nitrogen)

Isotope-Labeled Compounds